搜尋結果
LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. Hong Kong is the fifth approval, following approvals in the U.S., Japan, China, and South Korea. LEQEMBI’s approval in Hong Kong is based on the large global Phase 3 Clarity AD study.
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
Eisai Co., Ltd. announced that the following Directors and Corporate Officers for FY2024 were appointed by resolutions at the 112th Ordinary General Meeting of Shareholders and subsequent Board of Directors meeting held today. Directors (*Outside Directors) Board of Directors.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses i...
Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. About Eisai Co., Ltd.
In collaboration with Eisai, a major Chinese medical insurance company has developed and launched a healthcare insurance plan specifically for AD including partial coverage of the drug cost.
Eisai Announces Acquisition of Own Shares and Cancellation of Treasury Shares. Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act.
